These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 29241898)
1. Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease. Marshall T; Pugh A; Fairchild A; Hass S Value Health; 2017 Dec; 20(10):1383-1393. PubMed ID: 29241898 [TBL] [Abstract][Full Text] [Related]
2. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease. Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905 [TBL] [Abstract][Full Text] [Related]
3. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When? Dijk JM; Espay AJ; Katzenschlager R; de Bie RMA J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333 [TBL] [Abstract][Full Text] [Related]
4. Neurologists' preferences for device-aided therapy for advanced Parkinson's disease in Japan. Fujioka S; Mishima T; Yamazaki T; Bebrysz M; Nomoto M; Yamaguchi J; Fujimura K; Migita H; Aballéa S; Tsuboi Y Curr Med Res Opin; 2023 Jan; 39(1):91-104. PubMed ID: 36217768 [TBL] [Abstract][Full Text] [Related]
5. [Device-aided therapies in advanced Parkinson's disease]. Timofeeva AA Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627 [TBL] [Abstract][Full Text] [Related]
6. Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach. Fabbri M; Rosa MM; Ferreira JJ Drugs Aging; 2018 Dec; 35(12):1041-1054. PubMed ID: 30318555 [TBL] [Abstract][Full Text] [Related]
7. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604 [TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606 [TBL] [Abstract][Full Text] [Related]
9. [Continuous treatment with levodopa of Parkinson disease]. Lundqvist C; Nystedt T; Reiertsen O; Grotli R; Beiske AG Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2638-40. PubMed ID: 16215609 [TBL] [Abstract][Full Text] [Related]
10. Patient and Public Preferences for Treatment Attributes in Parkinson's Disease. Weernink MGM; van Til JA; Groothuis-Oudshoorn CGM; IJzerman MJ Patient; 2017 Dec; 10(6):763-772. PubMed ID: 28508354 [TBL] [Abstract][Full Text] [Related]
11. [Treatment possibilities in advanced Parkinson's disease]. Takáts A; Nagy H; Radics P; Tóth A; Tamás G Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235 [TBL] [Abstract][Full Text] [Related]
12. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901 [TBL] [Abstract][Full Text] [Related]
13. Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. Buhmann C; Hilker R; Lingor P; Schrader C; Schwarz J; Wolz M; Reichmann H J Neural Transm (Vienna); 2017 Aug; 124(8):1005-1013. PubMed ID: 28229223 [TBL] [Abstract][Full Text] [Related]
14. Device-Aided Treatment Strategies in Advanced Parkinson's Disease. Timpka J; Nitu B; Datieva V; Odin P; Antonini A Int Rev Neurobiol; 2017; 132():453-474. PubMed ID: 28554418 [TBL] [Abstract][Full Text] [Related]
15. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia. Williams DR; Evans AH; Fung VSC; Hayes M; Iansek R; Kimber T; O'Sullivan JD; Sue CM Intern Med J; 2017 Oct; 47(10):1107-1113. PubMed ID: 28195385 [TBL] [Abstract][Full Text] [Related]
19. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. Volkmann J; Albanese A; Antonini A; Chaudhuri KR; Clarke CE; de Bie RM; Deuschl G; Eggert K; Houeto JL; Kulisevsky J; Nyholm D; Odin P; Østergaard K; Poewe W; Pollak P; Rabey JM; Rascol O; Ruzicka E; Samuel M; Speelman H; Sydow O; Valldeoriola F; van der Linden C; Oertel W J Neurol; 2013 Nov; 260(11):2701-14. PubMed ID: 23287972 [TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion. Sydow O FEBS J; 2008 Apr; 275(7):1370-1376. PubMed ID: 18279380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]